Galmed Pharmaceuticals Ltd was incorporated in Israel on July 31, 2013. The Company operated under the parent company, Galmed Holdings Inc., as a holding company. The Company is a development stage company. The Company is a clinical-stage biopharmaceutical company that is engaged in the development and commercialization of oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class synthetic fatty-acid/bile-acid conjugate, or FABAC, called aramchol. Aramchol has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis, or NASH. The Company is subject to environmental, health and safety, and other laws and regulations in multiple jurisdictions.